Moreover, we also observed that USP44 expression was negatively associated with BRAFV600E mutation, tumor stage, histological type, extrathyroidal extension and thyroid gland disorder history, and reduced USP44 expression was positively correlated with poor clinical outcomes of patients. This evidence concerns the gene USP44 and neoplasm.